Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte,…
$ARKG Genomes acting well $TWST $SDGR $TXG $VCYT etc https://t.co/XxKtomLF9a
13 analysts rate VCYT Buy on consensus.
Consensus price target: $58.42 (+143.42% upside from $24.00)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Bhanji Muna director | Oct 19, 2026 | Sale | 1,864 | $81.46K |
| Leite John Global Chief Commercial Off | Sep 21, 2026 | Sale | 4,015 | $160.6K |
| Holstein Jens director | Sep 14, 2026 | Sale | 5,000 | $204.75K |
| Febbo Phillip G. Chief Scientific & Med Officer | Sep 4, 2026 | Sale | 10,405 | $446.3K |
| McGuire Annie EVP, General Counsel | Sep 4, 2026 | Sale | 2,154 | $92.17K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $517.15M | +16.01% | $66.35M |
| 2024 | $445.76M | +23.46% | $24.14M |
| 2023 | $361.05M | +21.76% | $-74.4M |
Stock data for VCYT: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics